On April 30, 2026, Contineum Therapeutics, Inc. announced positive topline results from its PIPE-791 Phase 1b trial in chronic pain, involving 43 patients, showing pain reduction scores significantly better than placebo. The trial reported mild to moderate adverse events, confirming safety and tolerability of the treatment.